Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 7/20 | 0.46 |
| ▸ | CTSS | P25774 | 7/20 | 0.46 |
| ▸ | CTSK | P43235 | 7/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346099 | 0.96 | CTSB (0.49) | CYP3A4SMN1; SMN2CTSBCTSSCTSK | |
| SCHEMBL346403 | 0.81 | CTSB (0.67) | CYP3A4SMN1; SMN2CTSBCTSSCTSK | |
| SCHEMBL346404 | 0.81 | CTSB (0.67) | CYP3A4SMN1; SMN2CTSBCTSSCTSK | |
| SCHEMBL346446 | 0.79 | CTSS (0.67) | CYP3A4CTSBCTSSCTSKCYP2C9 | |
| SCHEMBL346447 | 0.79 | CTSS (0.67) | CYP3A4CTSBCTSSCTSKCYP2C9 | |
| SCHEMBL346133 | 0.76 | CTSB (0.72) | CYP3A4SMN1; SMN2CTSBCTSSCTSK | |
| SCHEMBL346132 | 0.76 | CTSB (0.72) | CYP3A4SMN1; SMN2CTSBCTSSCTSK | |
| SCHEMBL347076 | 0.75 | CTSB (0.65) | CYP3A4CTSBCTSSCTSKCYP2C9 | |
| SCHEMBL347075 | 0.75 | CTSB (0.65) | CYP3A4CTSBCTSSCTSKCYP2C9 | |
| SCHEMBL346507 | 0.74 | CTSB (0.64) | CYP3A4SMN1; SMN2CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-8039480-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | CYP3A4 354/4885SMN1; SMN2 3535/4885CTSB 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.